Log In
Print
BCIQ
Print
Print this Print this
 

AGS-003

  Manage Alerts
Collapse Summary General Information
Company Argos Therapeutics Inc.
DescriptionSecond-generation RNA-loaded autologous dendritic cell immunotherapy
Molecular Target Not applicable
Mechanism of ActionImmunotherapy
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase III
Standard IndicationRenal cancer
Indication DetailsFirst-line treatment of advanced renal cell carcinoma (RCC); Treat metastatic renal cell carcinoma (RCC)
Regulatory Designation

U.S. - Fast Track (Treat metastatic renal cell carcinoma (RCC));
U.S. - Special Protocol Assessment (Treat metastatic renal cell carcinoma (RCC))

Partner

Chongqing Lummy Pharmaceutical Co. Ltd.; Green Cross Corp.; Pharmstandard OJSC


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$40.1M

0

$30.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today